Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
J Nucl Med
    August 2026
  1. JAFARVAND M, Farolfi A, Mei R, Djaileb L, et al
    PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study.
    J Nucl Med. 2026 Aug 20:jnumed.125.271556. doi: 10.2967/jnumed.125.271556.
    >> Share

  2. PARK HL, Kersting D, Bergstrom CP, Khaki AR, et al
    Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [(177)Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2026 Aug 13:jnumed.126.272651. doi: 10.2967/jnumed.126.272651.
    >> Share

  3. IRAVANI A, Gulati R, Miyaoka R, Reiger AC, et al
    Clinical Trial Protocol for LPS-Boost: Intensified [(177)Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
    J Nucl Med. 2026 Aug 13:jnumed.126.272472. doi: 10.2967/jnumed.126.272472.
    >> Share

  4. BEKKHOUCHA A, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of [(18)F]FDG PET Combined with [(68)Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2026 Aug 13:jnumed.126.273113. doi: 10.2967/jnumed.126.273113.
    >> Share

  5. BAILLY C, Vija L, Somme F, Massard V, et al
    Real-World Outcomes of [(177)Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2026 Aug 6:jnumed.126.272721. doi: 10.2967/jnumed.126.272721.
    >> Share

  6. CHAN JC, Carroll MT, Hitchen N, Hudson J, et al
    Thrombotic Microangiopathy in Patients Treated with (177)Lu-PSMA Combination Therapies.
    J Nucl Med. 2026;67:1254-1260.
    >> Share

    July 2026
  7. ELLS Z, Meyer C, Masri K, Ryhiner M, et al
    Tumor and Organ Dose Estimates from (177)Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
    J Nucl Med. 2026 Jul 30:jnumed.126.272574. doi: 10.2967/jnumed.126.272574.
    >> Share

  8. KARIMZADEH A, Futterer C, Hansen K, Coban O, et al
    Outcome Prediction After [(177)Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [(68)Ga]Ga-PSMA-11 PET-Based Model with [(18)F]F-Flotufolastat.
    J Nucl Med. 2026 Jul 23:jnumed.125.270944. doi: 10.2967/jnumed.125.270944.
    >> Share

  9. RAVI P, Zhong C, Perez KJ, Xie W, et al
    Clinical Impact and Dynamics of Clonal Hematopoiesis with (177)Lu-PSMA-617 Therapy in Advanced Prostate Cancer.
    J Nucl Med. 2026 Jul 16:jnumed.126.272125. doi: 10.2967/jnumed.126.272125.
    >> Share

  10. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
    Update to "Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy".
    J Nucl Med. 2026 Jul 16:jnumed.126.265448e. doi: 10.2967/jnumed.126.265448.
    >> Share

  11. MIYAHIRA A, Czernin J
    An Immunologist's Path Toward Advancing the Scientific Mission of the Prostate Cancer Foundation: Andrea Miyahira Talks with Johannes Czernin About the Role of the Prostate Cancer Foundation and Cancer Treatment.
    J Nucl Med. 2026 Jul 16:jnumed.126.273264. doi: 10.2967/jnumed.126.273264.
    >> Share

  12. HEKIMSOY T, Sauter AP, Tauber R, Horn T, et al
    Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined (18)F-Flotufolastat PSMA PET and mpMRI.
    J Nucl Med. 2026 Jul 2:jnumed.125.271916. doi: 10.2967/jnumed.125.271916.
    >> Share

  13. BUTTNER T, Hoffmann C, Essler M, Gartner F, et al
    Quantifying the Renal Impact of [(177)Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry.
    J Nucl Med. 2026;67:1086-1089.
    >> Share

    June 2026
  14. KASHYAP R, Buteau JP, Papa N, Ayati N, et al
    Prognostic Value of Restaging [(18)F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2026 Jun 25:jnumed.126.272531. doi: 10.2967/jnumed.126.272531.
    >> Share

  15. BAUCKNEHT M, Belgioia L, Albano D, Triggiani L, et al
    Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.
    J Nucl Med. 2026 Jun 11:jnumed.125.271680. doi: 10.2967/jnumed.125.271680.
    >> Share

  16. PAULE A, Masson S, Rose Dite Modestine J, Kara N, et al
    Role of (18)F-PSMA PET/MRI in Prostate Cancer Recurrence After Prostatectomy.
    J Nucl Med. 2026 Jun 4:jnumed.126.272126. doi: 10.2967/jnumed.126.272126.
    >> Share

  17. JIA KY, Kuten J, Jia HY, Bent EH, et al
    Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing (68)Ga-PSMA PET/CT.
    J Nucl Med. 2026 Jun 4:jnumed.126.272009. doi: 10.2967/jnumed.126.272009.
    >> Share

  18. CAKAL BA, Pirkovets K, Ottens VA, Zuur L, et al
    Actionable Feedback on Signal-to-Background Ratios During Drop-in Radioguided Surgery.
    J Nucl Med. 2026;67:864-870.
    >> Share

    May 2026
  19. GUBERINA N, Karpinski MJ, Guberina M, Hoberuck S, et al
    Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.
    J Nucl Med. 2026 May 21:jnumed.125.271770. doi: 10.2967/jnumed.125.271770.
    >> Share

  20. ULANER GA, Lam R
    Widespread Prostate Cancer Osseous Metastases: Negative on (18)F-Piflufolastat PET but Positive on (18)F-Fluciclovine PET.
    J Nucl Med. 2026 May 6:jnumed.125.272001. doi: 10.2967/jnumed.125.272001.
    >> Share

    April 2026
  21. CHAUHAN A, Hendifar AE, El-Haddad G, Soares HP, et al
    The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond.
    J Nucl Med. 2026 Apr 30:jnumed.126.272026. doi: 10.2967/jnumed.126.272026.
    >> Share

  22. BROSCH-LENZ J, Buther F, Oehler S, Ciamarone A, et al
    Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [(68)Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer.
    J Nucl Med. 2026 Apr 30:jnumed.125.271933. doi: 10.2967/jnumed.125.271933.
    >> Share

  23. KIRCHHOFF S, Erber B, Rauscher I, Sasse D, et al
    Prognostic Value of [(18)F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.
    J Nucl Med. 2026 Apr 22:jnumed.125.271488. doi: 10.2967/jnumed.125.271488.
    >> Share

  24. LING SW, Konijnenberg M, Segbers M, Hooijman E, et al
    Phase 1 Dose-Escalation Study of [(225)Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.
    J Nucl Med. 2026 Apr 22:jnumed.125.271880. doi: 10.2967/jnumed.125.271880.
    >> Share

  25. MISHRA A, Lisok A, Mease RC, Novakova Z, et al
    PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.
    J Nucl Med. 2026 Apr 22:jnumed.125.271053. doi: 10.2967/jnumed.125.271053.
    >> Share

  26. SHIOTA M, Fujiwara M, Sumiyoshi T, Enokida H, et al
    Circulating Tumor DNA Genomic Profiling in (223)Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.
    J Nucl Med. 2026 Apr 16:jnumed.126.272073. doi: 10.2967/jnumed.126.272073.
    >> Share

  27. UNTERRAINER LM, Ndlovu H, Hope TA, Unterrainer M, et al
    Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2026 Apr 16:jnumed.125.271598. doi: 10.2967/jnumed.125.271598.
    >> Share

  28. METSER U, Bauman G, Rashid M, Mirshahvalad SA, et al
    Utility of PSMA PET/CT After an Initial Negative Scan: Results from a Prospective Multicenter PSMA PET Registry.
    J Nucl Med. 2026 Apr 16:jnumed.126.272204. doi: 10.2967/jnumed.126.272204.
    >> Share

  29. ELLS Z, Meyer C, Kimura K, Wilhalme H, et al
    Dosimetry Analysis of (177)Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
    J Nucl Med. 2026 Apr 2:jnumed.125.271467. doi: 10.2967/jnumed.125.271467.
    >> Share

    March 2026
  30. HOANG TT, Bauer D, Ingham A, Miranda IC, et al
    Delta-like Ligand 3-Directed (225)Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.
    J Nucl Med. 2026 Mar 26:jnumed.125.271302. doi: 10.2967/jnumed.125.271302.
    >> Share

  31. WIDJAJA L, Hornfeck J, Siegmund SC, Gildehaus FJ, et al
    Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [(177)Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics.
    J Nucl Med. 2026 Mar 26:jnumed.125.271859. doi: 10.2967/jnumed.125.271859.
    >> Share

  32. GOGEBAKAN KC, Kunst N, Ghodsi A, Owens L, et al
    Cost-Effectiveness Analysis of (177)Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective.
    J Nucl Med. 2026 Mar 19:jnumed.125.271825. doi: 10.2967/jnumed.125.271825.
    >> Share

  33. GHODSI A, Demirci RA, Gulati R, Nelson PS, et al
    Prognostic Value of Cycle 1 SPECT SUV(mean) in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA-617.
    J Nucl Med. 2026 Mar 12:jnumed.125.271593. doi: 10.2967/jnumed.125.271593.
    >> Share

  34. KASSAS M, Jaafari A, Shagera QA, Devriendt L, et al
    SPECT Versus PET for [(177)Lu]Lu-PSMA Response Assessment Using Quantitative RECIP 1.0.
    J Nucl Med. 2026 Mar 12:jnumed.125.271755. doi: 10.2967/jnumed.125.271755.
    >> Share

  35. MORADPOUR M, Moradi Tuchayi A, Yadav S, Jiang F, et al
    Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer.
    J Nucl Med. 2026 Mar 5:jnumed.125.271296. doi: 10.2967/jnumed.125.271296.
    >> Share

    February 2026
  36. BIO IDRISSOU M, Aguiar Ferreira C, Comas Rojas H, Lambert Lepesevich LH, et al
    Preclinical Evaluation of [(177)Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer.
    J Nucl Med. 2026 Feb 26:jnumed.125.271543. doi: 10.2967/jnumed.125.271543.
    >> Share

  37. KIANI I, Siri MA, Babaei M, Aliasghari MM, et al
    Quantitative PSMA PET Biomarkers for Predicting Response to (177)Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis.
    J Nucl Med. 2026 Feb 26:jnumed.125.270872. doi: 10.2967/jnumed.125.270872.
    >> Share

  38. CHAUSSE G, Hou X, Uribe C, Harsini S, et al
    First-in-Human Evaluation of [(68)Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer.
    J Nucl Med. 2026 Feb 26:jnumed.123.266357. doi: 10.2967/jnumed.123.266357.
    >> Share

  39. PEPIN A, Doucette A, Narayan VK, Maxwell KN, et al
    Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2026 Feb 19:jnumed.125.270757. doi: 10.2967/jnumed.125.270757.
    >> Share

  40. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    Biochemical Recurrence-Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging.
    J Nucl Med. 2026 Feb 12:jnumed.125.271423. doi: 10.2967/jnumed.125.271423.
    >> Share

  41. NIKITAS J, Holzgreve A, Juarez J, Kimura K, et al
    Phase 2 Prospective Trial of Retreatment with [(177)Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.
    J Nucl Med. 2026 Feb 12:jnumed.125.271231. doi: 10.2967/jnumed.125.271231.
    >> Share

  42. KIMURA K, Murthy V, Voter AF, Solnes LB, et al
    PSMA PET/CT-Derived Indicators and Outcomes After [(177)Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program.
    J Nucl Med. 2026 Feb 12:jnumed.125.270789. doi: 10.2967/jnumed.125.270789.
    >> Share

    January 2026
  43. LI Y, Yang J, Chen B, Xiao L, et al
    Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value.
    J Nucl Med. 2026 Jan 29:jnumed.125.271410. doi: 10.2967/jnumed.125.271410.
    >> Share

  44. WIDJAJA L, Siegmund SC, Gildehaus FJ, Delker A, et al
    PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [(225)Ac]Ac-PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2026 Jan 29:jnumed.125.270677. doi: 10.2967/jnumed.125.270677.
    >> Share

  45. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study.
    J Nucl Med. 2026 Jan 29:jnumed.125.271173. doi: 10.2967/jnumed.125.271173.
    >> Share

  46. ABDEL-WAHAB M, Giammarile F
    Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.
    J Nucl Med. 2026 Jan 8:jnumed.125.271268. doi: 10.2967/jnumed.125.271268.
    >> Share

    December 2025
  47. MOAR EF, Keilholz M, Sheikh GT, Werner RA, et al
    PSMA PET-Positive Local Recurrences in the Prostate Bed Region and Their Coverage Based on Clinical Target Volume Delineation Guidelines from ESTRO-ACROP, PERYTON, FROGG, GFRU, and RTOG.
    J Nucl Med. 2025 Dec 30:jnumed.125.271324. doi: 10.2967/jnumed.125.271324.
    >> Share

  48. MAURER A, Muehlematter UJ, Sivakumar T, Mortezavi A, et al
    High-Intensity Focused Ultrasound in Prostate Cancer: Can PSMA PET Improve Focal Therapy Outcomes?
    J Nucl Med. 2025 Dec 4:jnumed.125.271318. doi: 10.2967/jnumed.125.271318.
    >> Share

  49. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [(177)Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
    J Nucl Med. 2025 Dec 4:jnumed.125.270916. doi: 10.2967/jnumed.125.270916.
    >> Share

  50. MILLER SR, Chung DH, Gonzalez RT, Jackson WC, et al
    Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.
    J Nucl Med. 2025;66:1891-1897.
    >> Share

    November 2025
  51. GABLER N, Kirchhoff S, Sauter A, Heck M, et al
    [(18)F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results.
    J Nucl Med. 2025 Nov 25:jnumed.125.270435. doi: 10.2967/jnumed.125.270435.
    >> Share

  52. BUCH-OLSEN KM, Vilstrup MH, Hansen S, Poulsen MH, et al
    Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [(18)F]PSMA-1007 PET/CT and [(18)F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management.
    J Nucl Med. 2025 Nov 25:jnumed.125.270710. doi: 10.2967/jnumed.125.270710.
    >> Share

  53. WANG G, Lai Y, Chen D, Jin W, et al
    First-in-Human PET Imaging of Prostate Cancer Using [(68)Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [(68)Ga]Ga-AZ-NI-093.
    J Nucl Med. 2025 Nov 20:jnumed.125.270703. doi: 10.2967/jnumed.125.270703.
    >> Share

  54. GHEZZO S, Mapelli P, Cogrossi LL, Samanes Gajate AM, et al
    Diagnostic Accuracy of Fully Hybrid PET/MRI with [(68)Ga]Ga-PSMA-11 and [(68)Ga]Ga-RM2 in Detecting Primary Prostate Cancer: A Phase 2 Trial with Histology as Gold Standard.
    J Nucl Med. 2025 Nov 20:jnumed.125.269782. doi: 10.2967/jnumed.125.269782.
    >> Share

  55. HARTENBACH M, Rasul S, Grubmuller B, Kramer G, et al
    PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.
    J Nucl Med. 2025 Nov 20:jnumed.125.270404. doi: 10.2967/jnumed.125.270404.
    >> Share

  56. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, International IAEA Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270537. doi: 10.2967/jnumed.125.270537.
    >> Share

  57. HOEKSTRA RJ, Peeters L, Beulens A, Roef MJ, et al
    Prospective Histopathologic Comparison Between [(18)F]PSMA-1007 PET/CT and [(18)F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270650. doi: 10.2967/jnumed.125.270650.
    >> Share

  58. ORTNER G, Hoderlein X, Barbato F, Beyersdorff D, et al
    The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer.
    J Nucl Med. 2025 Nov 6:jnumed.125.270667. doi: 10.2967/jnumed.125.270667.
    >> Share

  59. MIRSHAHVALAD SA, Iravani A, Fendler WP, Maurer T, et al
    Rechallenge and Extended [(177)Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer.
    J Nucl Med. 2025 Nov 6:jnumed.125.270889. doi: 10.2967/jnumed.125.270889.
    >> Share

  60. KRAUSEWITZ P, Essler M, Gaertner FC, Attenberger U, et al
    Impact of Initial Prostate-Specific Membrane Antigen PET/CT Staging and Prostate-Specific Membrane Antigen-Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase 2 DEPROMP Trial.
    J Nucl Med. 2025 Nov 6:jnumed.125.271344. doi: 10.2967/jnumed.125.271344.
    >> Share

    October 2025
  61. DJAILEB L, Farolfi A, Rauscher I, Haghighatian M, et al
    Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [(177)Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Oct 30:jnumed.125.270239. doi: 10.2967/jnumed.125.270239.
    >> Share

  62. RAHBAR K, Giesel FL, Herrmann K, Yun M, et al
    Efficacy of [(18)F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Oct 23:jnumed.125.269818. doi: 10.2967/jnumed.125.269818.
    >> Share

  63. MILLER SR, Chung DH, Gonzalez RT, Jackson WC, et al
    Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.
    J Nucl Med. 2025 Oct 16:jnumed.125.270825. doi: 10.2967/jnumed.125.270825.
    >> Share

  64. KOEHLER D, Shenas F, Sauer M, Apostolova I, et al
    PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.
    J Nucl Med. 2025 Oct 16:jnumed.125.270242. doi: 10.2967/jnumed.125.270242.
    >> Share

  65. MADSEN C, Zacho HD, Fuglo D, Nielsen K, et al
    (18)F-PSMA PET/CT Versus (18)F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study.
    J Nucl Med. 2025 Oct 9:jnumed.125.270822. doi: 10.2967/jnumed.125.270822.
    >> Share

  66. CHEN DC, Buteau JP, Papa N, Akhurst T, et al
    Prognostic Value of Initial Imaging and PSA Change with [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
    J Nucl Med. 2025 Oct 9:jnumed.125.270804. doi: 10.2967/jnumed.125.270804.
    >> Share

  67. TEUNISSEN FR, Oprea-Lager DE, Peters SMB, Smeenk RJ, et al
    Current Developments in Combining External-Beam Radiotherapy and (177)Lu-Labeled PSMA Ligands for Prostate Cancer Treatment.
    J Nucl Med. 2025 Oct 3:jnumed.125.270465. doi: 10.2967/jnumed.125.270465.
    >> Share

  68. SARTOR O, Emmett L, Herrmann K
    Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer.
    J Nucl Med. 2025 Oct 3:jnumed.125.271144. doi: 10.2967/jnumed.125.271144.
    >> Share

  69. KUCUK NO, Coskun N, Araz M, Alan Selcuk N, et al
    Initial Multicenter Experience with [(161)Tb]Tb-PSMA in [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.
    J Nucl Med. 2025 Oct 3:jnumed.125.270952. doi: 10.2967/jnumed.125.270952.
    >> Share

  70. KARMANN A, Rose S, Herrmann K, Kratochwil C, et al
    alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer.
    J Nucl Med. 2025 Oct 3:jnumed.125.270940. doi: 10.2967/jnumed.125.270940.
    >> Share

  71. HOYVIK AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, et al
    Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.
    J Nucl Med. 2025 Oct 3:jnumed.125.270444. doi: 10.2967/jnumed.125.270444.
    >> Share


  72. Biomarkers in Prostate Cancer: What's in the Blood?
    J Nucl Med. 2025;66:6A.
    >> Share

    September 2025
  73. LIU F, Monterosso ME, Boucher D, Shakti S, et al
    Preclinical Evaluation of [(212)Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted alpha-Therapy for Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.269707. doi: 10.2967/jnumed.125.269707.
    >> Share

  74. HADASCHIK B, Gillessen S, Sartor O
    (177)Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270836. doi: 10.2967/jnumed.125.270836.
    >> Share

  75. GIRI VK, Kolodny GM, Garnick MB
    First-Line [(177)Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270704. doi: 10.2967/jnumed.125.270704.
    >> Share

  76. PEPIN A, Doucette A, Vapiwala N, Narayan VK, et al
    Safety of the Combination of External Beam Radiotherapy with (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270316. doi: 10.2967/jnumed.125.270316.
    >> Share

  77. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with (177)Lu-PSMA: A Retrospective, Single-Center Study.
    J Nucl Med. 2025 Sep 25:jnumed.125.269971. doi: 10.2967/jnumed.125.269971.
    >> Share

  78. BEINTNER-SKAWRAN S, Gafita A, Lorenzini T, Tauber R, et al
    [(68)Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.
    J Nucl Med. 2025 Sep 11:jnumed.125.269584. doi: 10.2967/jnumed.125.269584.
    >> Share

  79. KUNSCH J, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [(177)Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360 degrees Cadmium-Zinc-Telluride SPECT.
    J Nucl Med. 2025 Sep 11:jnumed.125.270358. doi: 10.2967/jnumed.125.270358.
    >> Share

    August 2025
  80. HOLZGREVE A, Delker A, Ells Z, Brosch-Lenz J, et al
    Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of (177)Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol.
    J Nucl Med. 2025 Aug 28:jnumed.125.269495. doi: 10.2967/jnumed.125.269495.
    >> Share

  81. ALTUNAY B, Schafer L, Morgenroth A, Pena Q, et al
    Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy.
    J Nucl Med. 2025 Aug 28:jnumed.125.270317. doi: 10.2967/jnumed.125.270317.
    >> Share

  82. GRKOVSKI M, Krebs SS, O'Donoghue JA, Kuten J, et al
    Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Aug 7:jnumed.125.270170. doi: 10.2967/jnumed.125.270170.
    >> Share

    July 2025
  83. DENIS CS, Cousin F, De Laere B, Vanwelkenhuyzen J, et al
    Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Jul 31:jnumed.125.269729. doi: 10.2967/jnumed.125.269729.
    >> Share

  84. CHEN Y, Zhang X, Wang X, Liu Y, et al
    Interspecies Variability in Biodistribution and PET Imaging Performance of [(18)F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer.
    J Nucl Med. 2025 Jul 17:jnumed.125.270069. doi: 10.2967/jnumed.125.270069.
    >> Share

  85. KOHAN A, Metser U, Luke W, Rashid M, et al
    A Prospective Provincial Registry of (18)F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men.
    J Nucl Med. 2025 Jul 3:jnumed.125.269653. doi: 10.2967/jnumed.125.269653.
    >> Share

  86. KASHYAP R, Buteau JP, Bressel M, Eifer M, et al
    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
    J Nucl Med. 2025 Jul 3:jnumed.125.269640. doi: 10.2967/jnumed.125.269640.
    >> Share

    June 2025
  87. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.
    J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996.
    >> Share

  88. BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al
    Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
    J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751.
    >> Share

  89. SCHMITL S, Kretschmer-Chott E, Patronas EM, Kramer G, et al
    Efficacy, Safety, Blood Kinetics, and (213)Bi Distribution Studies of [(225)Ac]Ac-SibuDAB in Prostate Cancer Patients.
    J Nucl Med. 2025 Jun 5:jnumed.125.269655. doi: 10.2967/jnumed.125.269655.
    >> Share

  90. FANTI S, Robles Barba JJ, Behr S, Maurer T, et al
    Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266.
    >> Share

  91. GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al
    Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
    J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071.
    >> Share

  92. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
    Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
    >> Share

    May 2025
  93. VAN RIEL JHHM, Donswijk ML, Brouwer C, Gerritsen WR, et al
    Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with (223)Ra Therapy in Daily Practice.
    J Nucl Med. 2025 May 22:jnumed.125.269746. doi: 10.2967/jnumed.125.269746.
    >> Share

  94. SATAPATHY S, Das CK, Goyal S, Sood A, et al
    (177)Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial.
    J Nucl Med. 2025 May 22:jnumed.125.269913. doi: 10.2967/jnumed.125.269913.
    >> Share

    April 2025
  95. HARSINI S, Soleimani M, Wilson D, Uribe C, et al
    A Phase I/II Study of [(177)Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol.
    J Nucl Med. 2025 Apr 30:jnumed.124.269064. doi: 10.2967/jnumed.124.269064.
    >> Share

  96. UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al
    Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
    J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431.
    >> Share

  97. DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al
    Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT.
    J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361.
    >> Share

    March 2025
  98. CHEN DC, Buteau JP, Emmett L, Alipour R, et al
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
    J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901.
    >> Share

  99. YANG H, Wang J, Wen X, Guo H, et al
    Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives (68)Ga/(177)Lu-LNC1011 as Prostate Cancer Theranostics.
    J Nucl Med. 2025 Mar 20:jnumed.124.268959. doi: 10.2967/jnumed.124.268959.
    >> Share

  100. TANG W, Qi L, Chen M, Zhang Y, et al
    Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study.
    J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189.
    >> Share

  101. BERNER K, Hernes E, Kvassheim M, Revheim ME, et al
    First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299.
    >> Share

  102. JEWELL KE, Buteau JP, Medhurst E, Kwan EM, et al
    Safety and Efficacy of 20 Cycles of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269447. doi: 10.2967/jnumed.124.269447.
    >> Share

  103. FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al
    Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508.
    >> Share

  104. JOHNSTONE CN, Osellame LD, Cao Z, McDonald AF, et al
    DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of (177)Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
    J Nucl Med. 2025;66:385-390.
    >> Share

    February 2025
  105. TURCO F, Gillessen S, Herrmann K, Paone G, et al
    Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730.
    >> Share

  106. MURTHY V, Ludwig V, Gafita A, Hope TA, et al
    The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818.
    >> Share

  107. EIFER M, Sutherland DEK, Goncalves I, Buteau JP, et al
    Therapy-Related Myeloid Neoplasms After [(177)Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.
    J Nucl Med. 2025 Feb 20:jnumed.124.268640. doi: 10.2967/jnumed.124.268640.
    >> Share

  108. KOSTOS L, Buteau JP, Kong G, Tran B, et al
    Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.269252. doi: 10.2967/jnumed.124.269252.
    >> Share

  109. LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al
    Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318.
    >> Share

  110. DERLIN T, Widjaja L, Harke NN, Czerner C, et al
    (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319.
    >> Share

  111. VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al
    Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
    J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340.
    >> Share

  112. MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al
    Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy.
    J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719.
    >> Share

    January 2025
  113. LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al
    Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
    J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574.
    >> Share

  114. MADSEN C, Fuglo D, Pedersen M, Broholm R, et al
    Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
    J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275.
    >> Share

  115. MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al
    Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System.
    J Nucl Med. 2025;66:75-83.
    >> Share

  116. UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al
    Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
    J Nucl Med. 2025;66:54-60.
    >> Share

  117. ZAID NRR, Bastiaannet R, Hobbs R, Sgouros G, et al
    Mathematic Modeling of Tumor Growth During [(177)Lu]Lu-PSMA Therapy: Insights into Treatment Optimization.
    J Nucl Med. 2025;66:84-90.
    >> Share

  118. SCHWEIGER L, Maurer T, Simon R, Horn T, et al
    Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
    J Nucl Med. 2025;66:67-72.
    >> Share

    November 2024
  119. DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al
    PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
    J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167.
    >> Share

  120. WENZEL M, Koll F, Hoeh B, Humke C, et al
    Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807.
    >> Share

  121. DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al
    SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665.
    >> Share

  122. ZAGNI F, Vetrone L, Farolfi A, Vadala M, et al
    Feasibility of (177)Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer.
    J Nucl Med. 2024 Nov 7:jnumed.124.268062. doi: 10.2967/jnumed.124.268062.
    >> Share

  123. SAIDI A, Stallons TA, Wong AG, Torgue JJ, et al
    Preclinical Investigation of [(212)Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model.
    J Nucl Med. 2024;65:1769-1775.
    >> Share

    October 2024
  124. SONNI I, Weiner AB, Doddipalli S, Deol M, et al
    Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.
    J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443.
    >> Share

  125. HUANG RR, Zuo C, Mona CE, Holzgreve A, et al
    FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037.
    >> Share

  126. SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al
    Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606.
    >> Share

  127. MUNIZ M, Sartor O, Orme JJ, Koch RM, et al
    Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2024 Oct 30:jnumed.124.268277. doi: 10.2967/jnumed.124.268277.
    >> Share

  128. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    >> Share

  129. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
    Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
    >> Share

    September 2024
  130. MURTHY V, Voter AF, Nguyen K, Allen-Auerbach M, et al
    Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
    J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816.
    >> Share

  131. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
    Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
    >> Share

  132. POULIOT F, Saad F, Rousseau E, Richard PO, et al
    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
    >> Share

  133. GAFITA A, Voter A, Shesadri S, Spitz A, et al
    Initial Experience with [(177)Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
    J Nucl Med. 2024 Sep 19:jnumed.124.267723. doi: 10.2967/jnumed.124.267723.
    >> Share

  134. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
    Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
    J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
    >> Share

  135. POSCHENRIEDER A, Taleska J, Schaetz L
    (177)Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
    J Nucl Med. 2024;65:1340-1342.
    >> Share

  136. BELGE BILGIN G, Burkett BJ, Bilgin C, Orme JJ, et al
    Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience.
    J Nucl Med. 2024;65:1402-1408.
    >> Share

    August 2024
  137. WONG AJN, Ko HS, Hofman MS
    Navigating the Future of Prostate Cancer Care: AI-Driven Imaging and Theranostics Through the Lens of RELAINCE.
    J Nucl Med. 2024 Aug 29:jnumed.124.267924. doi: 10.2967/jnumed.124.267924.
    >> Share

  138. THIN P, Hotta M, Gafita A, Grogan T, et al
    Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative (68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591.
    >> Share

  139. HO KV, Tatum DS, Watkinson L, Carmack T, et al
    Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
    J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667.
    >> Share

  140. MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al
    [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
    J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899.
    >> Share

  141. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
    Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
    >> Share

  142. OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al
    (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology.
    J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772.
    >> Share

  143. LI S, Nguyen A, Counter W, John NC, et al
    Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881.
    >> Share

  144. NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al
    Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922.
    >> Share

  145. ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al
    Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
    J Nucl Med. 2024;65:1210-1216.
    >> Share

    July 2024
  146. DUIN JJ, de Barros HA, van Leeuwen PJ, van der Poel HG, et al
    Reply: Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267658. doi: 10.2967/jnumed.124.267658.
    >> Share

  147. AH-THIANE L, Ferrer L, Supiot S, Rousseau C, et al
    Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267477. doi: 10.2967/jnumed.124.267477.
    >> Share

  148. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
    (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
    J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
    >> Share

  149. BUTEAU JP, Kostos L, Alipour R, Jackson P, et al
    Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [(161)Tb]Tb-PSMA-I&T.
    J Nucl Med. 2024 Jul 11:jnumed.124.267650. doi: 10.2967/jnumed.124.267650.
    >> Share

  150. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
    Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
    >> Share

  151. RATHKE H, Winter E, Bruchertseifer F, Rohrich M, et al
    Deescalated (225)Ac-PSMA-617 Versus (177)Lu/(225)Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
    J Nucl Med. 2024;65:1057-1063.
    >> Share

    June 2024
  152. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
    Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
    J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
    >> Share

  153. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
    Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
    J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
    >> Share

  154. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
    A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
    >> Share

  155. PHAM TT, Hungnes IN, Rivas C, Cleaver J, et al
    Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of (99m)Tc and (188)Re Theranostic Agents for Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.124.267450. doi: 10.2967/jnumed.124.267450.
    >> Share

  156. SEIFERT R, Telli T, Lapa C, Desaulniers M, et al
    Safety and Efficacy of Extended Therapy with [(177)Lu]Lu-PSMA: A German Multicenter Study.
    J Nucl Med. 2024;65:909-916.
    >> Share

    May 2024
  157. PANDIT-TASKAR N, O'Donoghue JA, Chetty D, Max S, et al
    A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416.
    >> Share

  158. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    >> Share

  159. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
    True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
    J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
    >> Share

  160. ZANG J, Yang Y, Chen S, Wang C, et al
    Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
    J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
    >> Share

  161. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
    Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
    >> Share

  162. MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al
    Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
    J Nucl Med. 2024;65:735-739.
    >> Share

    April 2024
  163. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    >> Share

  164. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    >> Share

  165. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    >> Share

  166. HUANG YY, Lin TC, Yang SH, Lai LS, et al
    [(177)Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy.
    J Nucl Med. 2024 Apr 18:jnumed.124.267533. doi: 10.2967/jnumed.124.267533.
    >> Share

  167. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
    Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
    J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
    >> Share

  168. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    >> Share

  169. BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al
    Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
    J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526.
    >> Share

  170. HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
    Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2024;65:566-572.
    >> Share

    March 2024
  171. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
    Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
    >> Share

  172. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    >> Share

  173. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
    Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
    J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
    >> Share

    February 2024
  174. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    >> Share

  175. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
    >> Share

  176. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    >> Share

  177. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    >> Share

  178. MAURER T, Thomas C, Hadaschik B
    The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?
    J Nucl Med. 2024 Feb 15:jnumed.123.267187. doi: 10.2967/jnumed.123.267187.
    >> Share

  179. KUMAR S, Crumbaker M, Emmett L
    Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:333-334.
    >> Share

  180. ASKARI E, Harsini S
    Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:332-333.
    >> Share

    January 2024
  181. LIGHT A, Lazic S, Houghton K, Bayne M, et al
    Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
    >> Share

  182. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
    Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
    J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
    >> Share

  183. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
    >> Share

  184. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
    >> Share

  185. RAVI KUMAR AS, Hofman MS
    Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.
    J Nucl Med. 2024;65:85-86.
    >> Share

  186. STEINHELFER L, Lunger L, Cala L, Pfob CH, et al
    Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy.
    J Nucl Med. 2024;65:79-84.
    >> Share

    December 2023
  187. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
    First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
    >> Share

  188. BENABDALLAH N, Lu P, Abou DS, Zhang H, et al
    Beyond Average: alpha-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 14:jnumed.123.266571. doi: 10.2967/jnumed.123.266571.
    >> Share

  189. JADVAR H
    Sequential and Combination Therapies of (223)RaCl(2) and Prostate-Specific Membrane Antigen Radioligand Therapy.
    J Nucl Med. 2023;64:1932-1933.
    >> Share

    November 2023
  190. EMMETT L, Papa N, Counter W, Calais J, et al
    Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
    J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
    >> Share

  191. WANG F, Liu C, Vidal I, Mana-Ay M, et al
    Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
    J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
    >> Share

  192. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
    Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
    J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
    >> Share

  193. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
    Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
    J Nucl Med. 2023 Nov 30:jnumed.123.265448. doi: 10.2967/jnumed.123.265448.
    >> Share

  194. SARTOR O, Ledet E, Huang M, Schwartz J, et al
    Prediction of Resistance to (177)Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.
    J Nucl Med. 2023;64:1721-1725.
    >> Share

    October 2023
  195. RAHBAR K, Essler M, Eiber M, la Fougere C, et al
    (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study).
    J Nucl Med. 2023 Oct 12:jnumed.123.266125. doi: 10.2967/jnumed.123.266125.
    >> Share

  196. MEYER C, Stuparu A, Lueckerath K, Calais J, et al
    Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer.
    J Nucl Med. 2023 Oct 5:jnumed.123.265433. doi: 10.2967/jnumed.123.265433.
    >> Share

  197. TSCHAN VJ, Busslinger SD, Bernhardt P, Grundler PV, et al
    Albumin-Binding and Conventional PSMA Ligands in Combination with (161)Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
    J Nucl Med. 2023;64:1625-1631.
    >> Share

  198. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:1632-1637.
    >> Share

  199. GRAVES SA
    Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2023;64:1567-1569.
    >> Share

  200. MERCOLLI L, Mingels C, Manzini G, Cumming P, et al
    [(177)Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease.
    J Nucl Med. 2023;64:1570-1573.
    >> Share

    September 2023
  201. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
    PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
    >> Share

  202. RINSCHEID A, Gable A, Wienand G, Pfob C, et al
    An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Sep 28:jnumed.123.265970. doi: 10.2967/jnumed.123.265970.
    >> Share

  203. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
    Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
    J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
    >> Share

  204. SATAPATHY S, Mittal BR, Sood A, Das CK, et al
    [(177)Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial.
    J Nucl Med. 2023 Sep 14:jnumed.123.266141. doi: 10.2967/jnumed.123.266141.
    >> Share

  205. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
    Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
    J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
    >> Share

  206. MURTHY V, Gafita A, Thin P, Nguyen K, et al
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
    J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
    >> Share

  207. KUMAR S, Crumbaker M, Harvey C, Pathmanandavel S, et al
    The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2023;64:1412-1416.
    >> Share

  208. MURTHY V, Allen-Auerbach M, Lam R, Owen D, et al
    PSMA-Negative Lesion Progression Under (177)Lu-PSMA Radioligand Therapy.
    J Nucl Med. 2023;64:1502-1503.
    >> Share

  209. HOPE TA, Antonarakis ES, Bodei L, Calais J, et al
    SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-PSMA-617 Radionuclide Therapy.
    J Nucl Med. 2023;64:1417-1423.
    >> Share

    August 2023
  210. VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al
    PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
    J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738.
    >> Share

  211. HOHBERG M, Reifegerst M, Drzezga A, Wild M, et al
    Prediction of Response to (177)Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC.
    J Nucl Med. 2023 Aug 31:jnumed.122.264953. doi: 10.2967/jnumed.122.264953.
    >> Share

  212. HOPE TA, Benz M, Jiang F, Thompson D, et al
    Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
    J Nucl Med. 2023 Aug 17:jnumed.123.265916. doi: 10.2967/jnumed.123.265916.
    >> Share

    July 2023
  213. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023 Jul 27:jnumed.123.265523. doi: 10.2967/jnumed.123.265523.
    >> Share

  214. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
    Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
    J Nucl Med. 2023 Jul 20:jnumed.123.265771. doi: 10.2967/jnumed.123.265771.
    >> Share

  215. STRAUB M, Kupferschlager J, Serna Higuita LM, Weissinger M, et al
    Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
    J Nucl Med. 2023 Jul 6:jnumed.122.264770. doi: 10.2967/jnumed.122.264770.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016